Japanese regulators have approved Eliquis, an anticlotting drug developed by Bristol-Myers...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Japanese regulators have approved Eliquis, an anticlotting drug developed by Bristol-Myers Squibb (BMY -0.6%) and Pfizer (PFE +0.2%). This is the third such approval for the treatment in less than two months, having also been approved by health regulators in the European Union and Canada. The FDA is currently considering its new drug application in the U.S., which was resubmitted in late September after the FDA requested additional information, and a decision is expected by mid-March next year.